

OCT 14 2009

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Geoffrey N. Holland, et al

Serial No.: 10/783,649

Filed: February 20, 2004

For: MEDICATION MANAGEMENT
SYSTEM

Attorney Docket No.: 7135USO4

Examiner: Robert D. Rines

Confirmation No.: 7346

Group Art Unit: 3686

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

Certificate of Facsimile Transmission
under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile to the Patent and Trademark Office by 11:59 PM Eastern Time on the date shown below addressed to:

MAIL STOP RCE
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Facsimile No: (571) 273-8300
Date :October 14, 2009

Michael R. Crabb 10/14/09
Michael R. Crabb Date

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation in an Application" on Form PTO-1449 for consideration by the Examiner. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists, and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of

10/15/2009 JVONG1 00000049 503118 10783649
03 FC:1806 180.00 DA

such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Because this Information Disclosure Statement is submitted after the mailing of a first Office Action on the merits of the application, the Commissioner is authorized to charge our Deposit Account, 50-3118 the required fee in the amount of \$180.00 and any additional fees (or credit any over payments) that may be required in association with this communication.

Customer No.
41155

HOSPIRA, INC.
Telephone: (224) 212-2889
Facsimile: (224) 212-2088

Respectfully submitted,
Geoffrey N. Holland, et al


Michael R. Crabb
Registration No. 37,298
Attorney for Applicants